Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 2Phase 1 2Phase NA 1Phase 2/3 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Stomach Neoplasms 5Rectal Neoplasms 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Ovarian Neoplasms 3Neoplasms 3Carcinoma, Hepatocellular 3Breast Neoplasms 3Uterine Cervical Neoplasms 2Small Cell Lung Carcinoma 2Sarcoma 2Pancreatic Neoplasms 2Melanoma 2Lung Neoplasms 2Esophageal Squamous Cell Carcinoma 2Colorectal Neoplasms 2Sarcoma, Ewing 1SCLC 1Retinoblastoma 1Osteosarcoma 1Oligometastatic Disease 1Neoplasms, Germ Cell and Embryonal 1Nasopharyngeal Carcinoma 1NSCLC 1Mouth Neoplasms 1Lymphoma, Follicular 1Lymphoma 1Locally Advanced Resectable Rectal Cancer 1Kidney Neoplasms 1Head and Neck Neoplasms 1Glioblastoma 1

Interventions

Nivolumab 3Ramucirumab 2Radiotherapy 2Paclitaxel 2Cisplatin 2Capecitabine 2tucatinib 1Trastuzumab 1Taxes 1Specimen Handling 1Oxaliplatin 1Magnetic Resonance Spectroscopy 1Leucovorin 1Folfox protocol 1Fluorouracil 1Drug Therapy 1Cetuximab 1CP protocol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Adenocarcinoma Of Esophagus × Drug Therapy × Clear all
NCT07392892 2026-04-13

A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer

Pfizer

Phase 2/3 Recruiting
840 enrolled
Gastrointestinal

Adenocarcinoma Of Esophagus, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡